Fibrinogen human

DB09222ApprovedInvestigationalProtein Based TherapiesBlood Coagulation FactorsHemostatics

Fibrinogen human is a hemostatic agent used for the treatment of acute bleeding episodes in patients with acquired or congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia. It works by replacing a specific protein in the blood, fibrinogen (factor I), that helps with blood clotting.

Mechanism
Curator reviewed
Primary indication
Human fibrinogen is indicated for the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia.Curator reviewed · 12 structured indications
First approval
Canada, 2006 · United States, 1998 · European Union, 2016
Also known as
Coagulation Factor I · Factor I (fibrinogen) · Factor I human · Fibrinogen · Fibrinogen (human)
Brand names
  • Artiss
  • Evarrest
  • Evicel
  • Fesilty
  • Fibryga
  • Riastap
  • Tachosil
  • Tisseel
  • Veraseal
  • Vistaseal

Resolves to

Clinical / RWD

What you can answer from here — as of July 03, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
91Drug interactionsStructured to mechanism, not free text
Sign in
160Clinical trialsPhase, status and sponsor resolved per trial
Sign in
12Structured indicationsCondition, population, route and combination as fields, not prose
Sign in
161Marketed productsAcross 10 countries and 29 labellers
Sign in
1ATC codeIncluding every combination product, plus 11 drug categories
Sign in
8+ReferencesStructured and connected to the statements they support
Sign in

Which other approved drugs treat the same conditions as Fibrinogen human, and which companies have late-stage candidates in those indications?

Create a free account or log in to explore the full data card.

Create Account